Kedrion and Kamada announce collaboration for Anti Covid-19 IgG
Kamada is Responsible for Product Development, Manufacturing, Clinical Development, and Regulatory Submissions, as well as Distribution in Territories not under Kedrion’s Responsibility Kedrion is Responsible for the Collection and Supply of Plasma from Convalescent COVID-19 Patients, Support of Clinical Development and Distribution in the U.S., Europe, Australia, and S. Korea Rehovot, Israel and Castelvecchio
World Hemophilia Day: socially distant but still united with patients
Now more than ever, Kedrion is renewing its commitment to those who live with this rare disorder
Kedrion supports live streaming of medical debate on the use of convalescent plasma to treat Covid-19
Online roundtable “The Gift of the Cured versus the Pandemic” on air at DonatoriH24 on April 16
Coronavirus, from Plasma an anti Covid-19 treatment
Kedrion’s commitment to find a treatment from convalescent patient plasma
Letter to patient associations and scientific organizations
Communication from Paolo Marcucci, Chairman & CEO of Kedrion
Kedrion Statement on the novel Coronavirus
In accordance with international, national and local authority guidelines, Kedrion has acted immediately in dealing with the epidemiological emergency linked to the spread of the novel Coronavirus, and has taken all necessary measures to safeguard the health and safety of its employees and guarantee continuation of business activities. Paolo Marcucci, Chairman & CEO has stated:
Kedrion alongside IPOPI at the IPIC Congress in Madrid
The importance of early diagnosis and the most recent innovations in the treatment of PID patients were the focus
Kedrion keeps Hemophilia therapy debate flowing in Latin America
A recent CLAHT Congress symposium restates current and future role of replacement therapy
FSI SGR enters Kedrion share capital
The company continues with its growth and development strategy